Skip to main content

Table 4 Multivariable Cox regression analysis of disease specific survival

From: A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway

Variable Hazards ratio (95% CI) P value
Colon and rectal samples (N = 214)
 Age (< 60 vs. ≥ 60) 1.476 (1.085–2.008) 0.013
 Stage (I/II vs. III) 1.007 (0.657–1.544) 0.974
 Stage (I/II vs. IV) 1.862 (1.295–2.677) 0.001
 Neoadjuvant treatment (no vs. yes) 1.212 (0.879–1.673) 0.241
 SEPT9 methylation (non-Hyper. vs. hypermethylated) 0.673 (0.469–0.965) 0.031
Colon samples (N = 110)
 Age (< 60 vs. >=60) 1.730 (1.079–2.773) 0.023
 Stage (I/II vs. III) 0.966 (0.486–1.922) 0.922
 Stage (I/II vs. IV) 1.454 (0.859–2.463) 0.164
 Neoadjuvant treatment (no vs. yes) 1.237 (0.677–2.259) 0.490
 Tumor location (distal vs. proximal) 1.879 (1.174–3.007) 0.009
 SEPT9 methylation (non-Hyper. vs. hypermethylated) 0.472 (0.276–0.806) 0.006
  1. 95% CI 95% confidence interval, CRC colorectal cancer, non-Hyper. non-hypermethylated
  2. Italics values indicate statistically significant (P < 0.05)
\